Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus-eluting coronary stent - Lepu Medical Technology (Beijing)

Next Previous
Drug Profile

Sirolimus-eluting coronary stent - Lepu Medical Technology (Beijing)

Alternative Names: NeoVas BCS - Lepu Medical Technology; NeoVas bioresorbable coronary scaffold - Lepu Medical Technology

Latest Information Update: 30 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lepu Medical Technology (Beijing)
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Coronary artery disease

Most Recent Events

  • 06 Aug 2021 Lepu Medical Technology plans a clinical trail for Coronary artery disease in September 2021 (NCT04995159)
  • 26 Aug 2017 Efficacy data from a clinical trial in Coronary artery disease presented at the the ESC Congress 2017: Annual Congress of the European Society of Cardiology (ESC-2017)
  • 26 Aug 2017 Lepu Medical Technology (Beijing) completes the clinical trial in Coronary artery disease in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top